A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

NCT04061772 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Bortezomib
DRUG: Etoposide
DRUG: Cyclophosphamide
DRUG: Pharmorubicin
DRUG: Prednisone

Sponsor

Zhejiang Cancer Hospital